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Effect of informed consent on patient
characteristics in a stroke thrombolysis trial
ABSTRACT
Objective: To determine whether the manner of consent, i.e., informed consent by patients them-
selves or informed consent by proxy, affects clinical characteristics of samples of acute stroke
patients enrolled in clinical trials.
Methods: We analyzed the manner of obtaining informed consent in the first 1,005 patients from
WAKE-UP, an investigator-initiated, randomized, placebo-controlled trial of MRI-based thrombol-
ysis in stroke patients with unknown time of symptom onset running in 6 European countries. Pa-
tients providing informed consent by themselves were compared with patients enrolled by proxy
consent. Baseline clinical measures were compared between groups.
Results: In 359 (35.7%) patients, informed consent was by proxy. Patients with proxy consent
were older (median 71 vs 66 years, p , 0.0001) and had a higher frequency of arterial hyper-
tension (58.2% vs 43.4%, p , 0.0001). They showed higher scores on the NIH Stroke Scale
(median 11 vs 5, p, 0.0001) and more frequently aphasia (73.7% vs 20.0%, p, 0.0001). The
rate of proxy consent varied among countries (p , 0.0001), ranging from 77.1% in Spain to
1.2% in Denmark.
Conclusions: Patients recruited by proxy consent were older, had more severe strokes, and had
higher prevalence of aphasia than those with capacity to give personal consent. Variations in
the manner of consent across countries may influence trial results.
Clinicaltrials.gov and Clinicaltrialsregister.eu identifiers: NCT01525290 (clinicaltrials.gov);
2011-005906-32 (clinicaltrialsregister.eu). Neurology® 2017;89:1400–1407
GLOSSARY
DWI 5 diffusion-weighted imaging; FLAIR 5 fluid-attenuated inversion recovery; IQR 5 interquartile range; NIHSS 5 NIH
Stroke Scale.
As a general principle, any research involving humans requires voluntary participation based on
informed consent.1 This also applies to enrollment in clinical trials und usually requires participants
to give written informed consent after having received detailed information about potential benefits
and risks as well as alternative treatment options, and after having had adequate time for consid-
eration. Trials in acute stroke, however, present several challenges to this approach. Reperfusion
therapies in acute stroke show a clear time-dependent effect, being more effective the earlier
treatment is started, or reperfusion achieved.2,3 Both routine care and clinical trials in acute stroke
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are carried out under pressure of time. Thus,
time available for consideration is very short.
In addition, the brain injury commonly com-
promises language function, awareness of neu-
rologic deficits, conscious level, and physical
abilities, including vision and writing, relevant
to the usual consent process. Since most stroke
patients lack capacity to provide consent,4,5
alternative approaches are needed,6,7 and the
bias introduced by systematic exclusion of cer-
tain subgroups of stroke patients, e.g., those
with aphasia, has been reviewed critically.8
Previous stroke trials point towards possible
meaningful differences between patients able to
give consent by themselves and those enrolled
by proxy consent, with patients enrolled by
proxy consent being more severely affected.9,10
However, the number of studies addressing this
research question is small, and it is uncertain
how the manner of obtaining consent affects
further characteristics of stroke patients
enrolled in clinical trials and how this might
affect the generalizability of trial results. To
address this question, we analyzed data of the
first 1,005 patients enrolled in WAKE-UP,
a European multicenter randomized controlled
clinical trial of IV thrombolysis in acute stroke
patients with unknown time of symptom onset
based on MRI.11 We study the effect of the
manner of consent on the clinical characteris-
tics of patients enrolled. Moreover, we also
describe national variations in the manner of
obtaining informed consent, an issue that has
not yet been studied for acute stroke trials.
METHODS Study population. WAKE-UP (Efficacy and
safety of MRI-based thrombolysis in wake-up stroke: a rando-
mised, double-blind, placebo-controlled trial) is an investigator-
initiated, randomized, double-blind, placebo-controlled trial
designed to test the efficacy and safety of IV thrombolysis in
patients with unknown time of symptom onset selected by
MRI.11 Patients are screened with MRI including diffusion-
weighted imaging (DWI) and fluid-attenuated inversion recov-
ery (FLAIR), and the presence of a DWI–FLAIR mismatch
indicating ischemic stroke lesion ,4.5 hours12 represents the
main imaging criterion for randomization to treatment with
either IV tissue plasminogen activator or placebo. The trial was
started in September 2012. The present analysis includes baseline
data of patients enrolled until April 1, 2016. Only information
recorded at baseline was analyzed, and only data of patients with
at least information concerning informed consent, symptom
onset, age, and sex were included.
Standard protocol approvals, registrations, and patient
consents. WAKE-UP was approved by the national competent
authorities and ethics committees in all participating countries.
WAKE-UP was registered at clinicaltrials.gov (NCT01525290)
and clinicaltrialsregister.eu (2011-005906-32).
Informed consent has to be obtained prior to enrollment of pa-
tients in the trial. Options for proxy consent are given in accordance
with the following European and national regulations (figure 1):
A: The patient is judged to have capacity to give informed
consent and able to provide written consent: the patient provides
written consent.
B: The patient is judged to have capacity to give informed
consent but unable to provide written consent due to a physical
barrier: the patient provides witnessed oral consent and provides
later written consent as soon as possible.
C: The patient lacks capacity to give informed consent, legal
guardian is available: the legal guardian acts on behalf of the
patient and provides written consent.
D: The patient lacks capacity to give informed consent, legal
guardian is not available, informed consent by next of kin: next
acts on behalf of the patient following the patient’s presumed will
and provides written consent; patient or legal guardian provides
later written consent as soon as possible.
E: The patient lacks capacity to give informed consent, legal
guardian is not available, enrollment of patient by consensus
between investigator and independent physician: the patient may
be enrolled by consensus between the investigator and an indepen-
dent physician; if possible, patient’s next of kin should be contacted
to appraise the patient’s presumed will; the patient or legal guardian
provides later written consent as soon as possible.
F: The patient lacks capacity to give informed consent, legal
guardian is not available, enrollment of patient by investigator:
the patient may be enrolled by the investigator acting on behalf
of the patient following the patient’s presumed will; if possible,
the patient’s next of kin should be contacted to appraise the
patient’s presumed will; the patient or legal guardian provides
later written consent as soon as possible.
Clinical examinations and MRI at baseline. Neurologic
examination was performed by certified investigators using the
NIH Stroke Scale (NIHSS).13 Information on time of symptom
recognition and of the time point last seen well was obtained from
patients or caregivers, and the reason why exact symptom onset
was unknown was recorded according to 5 categories: night sleep,
day sleep, unwitnessed stroke with aphasia, unwitnessed stroke
with confusion, other. Time of admission to hospital was ob-
tained from the medical records.
MRI including DWI and FLAIR was performed according to
the trial protocol. Local investigators judged DWI–FLAIR mis-
match according to standards provided together with the study
protocol and after completion of a computer-based image judge-
ment training and certification. Presence of a visible acute ische-
mic lesion on DWI, DWI–FLAIR mismatch, and any signs of
intracranial haemorrhage were recorded.
Statistical analysis. Demographic and clinical characteristics as
well as imaging findings at baseline are described and compared
between groups. The following delays were calculated: time
between last seen well and symptom recognition, time between
symptom recognition and hospital admission, time between hos-
pital admission and informed consent, and time between hospital
admission and administration of the study drug. In addition to
the NIHSS sum score, presence of aphasia as assessed by item
9 of the NIHSS and disturbance of level of consciousness as as-
sessed by item 1a of the NIHSS were analyzed separately as cat-
egorical variables.
Descriptive statistics are provided including median (interquar-
tile range [IQR]) and percentages for continuous and categorical
data, respectively. For group comparison, the manner of informed
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consent was dichotomized into informed consent by the patient
personally (written or oral: A, B) or informed consent by proxy
(legal guardian, next of kin, consultant, or investigator: C, D, E, F).
The manner of obtaining informed consent was also compared
among countries for the 6 countries enrolling patients at the time
of database export (Belgium, Denmark, France, Germany, Spain,
United Kingdom). Fisher exact test or x2 test was used to com-
pare groups for categorical variables, and the Kruskal-Wallis test
was used for continuous variables. In order to account for
heterogeneity among countries, group comparisons were repeated
by fitting a logistic regression model of the odds of informed con-
sent given by proxy according to each factor adjusted for country.
All analyses are considered exploratory. SAS software, version 9.3
(SAS Institute Inc., Cary, NC) was used for all analyses.
RESULTS Of 1,039 patients enrolled in the trial,
1,005 patients met the inclusion criteria and were
included in the analysis. Median age was 68 years
(IQR 58–75 years); 38.8% of patients were women.
In 646 (64.3%) patients, informed consent was given
by the patients themselves, while in 359 (35.7%),
informed consent was by proxy (see table 1 for dis-
tribution of means of informed consent).
Patients enrolled via informed consent by proxy
were older (median 71 vs 66 years, p , 0.0001)
and were more frequently female (49.9% vs 32.7%,
p , 0.0001; table 2). They also had a longer delay
between the time point last seen normal and the time
of symptom recognition (8.9 vs 7.3 hours, p ,
0.0001). In contrast, the delay between symptom
recognition and hospital arrival was shorter (1.5 vs
1 hour, p , 0.0001). Regarding trial-related activi-
ties, the delays between hospital admission and
informed consent and between admission to hospital
Table 1 Means of informed consent used for enrollment
All (n 5 1,005)
Germany
(n 5 335)
Denmark
(n 5 242)
Belgium
(n 5 97)
France
(n 5 138)
United Kingdom
(n 5 101)
Spain
(n 5 92)
Patient written (A) 558 (55.5) 196 (58.5) 208 (86.0) 36 (37.1) 56 (40.6) 44 (43.6) 18 (19.6)
Patient oral (B) 88 (8.8) 29 (8.7) 31 (12.8) 11 (11.3) 9 (6.5) 5 (5.0) 3 (3.3)
Legal guardian (C) 56 (5.6) 3 (0.9) 3 (1.2) 14 (14.4) 8 (5.8) 20 (19.8) 8 (8.7)
Next of kin (D) 165 (16.4) 35 (10.4) 0 27 (27.8) 16 (11.6) 25 (24.8) 62 (67.4)
Consultant (E) 80 (8.0) 72 (21.5) 0 1 (1.0) 0 7 (7.0) 0
Investigator (F) 58 (5.8) 0 0 8 (8.2) 49 (35.5) 0 1 (1.1)
All values n (%); the distribution of means of informed consent was significantly different by country (p , 0.0001, x2 test).
Figure 1 Approaches to informed consent in WAKE-UP
The different means of obtaining informed consent in WAKE-UP depending on the ability of the patient to give informed consent and on the availability of
a legal guardian. The means of informed consent allowed for patient enrollment differed by country according to national regulations and the approval of
national and regional ethics committees.
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and the start of study drug, respectively, were longer
for patients with informed consent by proxy, but in
the additional analysis adjusted for country, no sig-
nificant association was found.
Arterial hypertension was observed more fre-
quently in patients with informed consent by proxy
(58.2% vs 43.4%, p 5 0.0022). Diabetes mellitus,
hypercholesterolemia, and atrial fibrillation also were
observed more frequently in patients with proxy con-
sent, but the difference was not significant after
adjustment for country. Patients enrolled via
informed consent by proxy presented with a more
severe neurologic deficit on admission, reflected by
higher values on the NIHSS (median 11 vs 5, p ,
0.0001). They also showed more frequently aphasia
(73.7% vs 20.0%, p, 0.0001) and disturbed level of
consciousness (17.0% vs 3.4%, p , 0.0001). Of
note, MRI findings (i.e., findings of intracranial hae-
morrhage, acute DWI lesions, and DWI–FLAIR
mismatch) did not differ between groups.
The relative frequency of the manner of informed
consent used for enrollment varied among countries
(p , 0.001; table 1). Written consent by patients
themselves was the most frequent manner of
informed consent in all countries apart from Spain
(ranging from 86.0% in Denmark to 19.6% in
Spain). Informed consent by next of kin ranged from
67.4% in Spain to not being used at all in Denmark.
Enrollment by independent physician was used in
21.2% of cases in Germany but was only rarely used
in other countries. In contrast, enrollment by inves-
tigator was common in France (35.5%), less frequent
in Belgium (8.2%), but only used in single cases in
the other countries. Overall, the proportion of
Table 2 Clinical characteristics by means of informed consent
Informed consent by
patient (n 5 646)
Informed consent by
proxy (n 5 359)
Group comparison
p value (unadjusted)
Group comparison
p value (adjusted
for country)a
Age, y, median (IQR) 66 (56–73) 71 (62–76) ,0.0001 ,0.0001
Female sex, n (%) 211 (32.7) 179 (49.9) ,0.0001 ,0.0001
Delay between last seen well and symptom
recognition, h, median (IQR) [n]
7.3 (5.0–8.8) [593]b 8.9 (6.5–11.0) [290]b ,0.0001 ,0.0001
Delay between symptom recognition and
admission to hospital, h, median (IQR) [n]
1.9 (1.3–2.7) [643]b 1.5 (1.0–2.2) [345]b ,0.0001 ,0.0001
Delay between admission to hospital and
informed consent, h, median (IQR) [n]
0.33 (0.17–0.75) [611]b 0.56 (0.30–0.93) [332]b ,0.0001 0.99
Delay between admission to hospital and
IMP administration, h, median (IQR) [n]
1.20 (0.92–1.52) [247]b 1.54 (1.17–1.90) [110]b ,0.0001 0.41
Medical history/risk factors,b n (%)
Arterial hypertension 269/620 (43.4) 203/349 (58.2) ,0.0001 0.0022
Diabetes mellitus 84/618 (6.2) 75/349 (21.5) 0.0015 0.24
Hypercholesterolemia 158/600 (26.3) 117/335 (34.9) 0.0057 0.061
Atrial fibrillation 38/614 (6.2) 36/345 (10.4) 0.018 0.24
Ischemic stroke 75/624 (12.0) 45/349 (12.9) 0.69 0.81
TIA 32/621 (5.2) 14/346 (4.1) 0.44 0.11
Intracranial haemorrhage 1/625 (0.2) 1/346 (0.3) 0.67 0.22
Gastrointestinal bleeding 12/623 (1.9) 3/350 (0.9) 0.19 0.033
NIHSS on admission, median (IQR) 5 (3–7) 11 (7–17) ,0.0001 ,0.0001
Aphasia, n (%) 128/639 (20.0) 264/358 (73.7) ,0.0001 ,0.0001
Disturbed level of consciousness (NIHSS
LOC item 1a >1), n (%)
22/639 (3.4) 61/358 (17) ,0.0001 ,0.0001
MRI findings, n (%)
Intracranial hemorrhagec 42/624 (6.7) 30/345 (8.7) 0.26 0.60
Acute DWI lesion 514/624 (82.4) 279/333 (83.8) 0.58 0.86
DWI–FLAIR mismatch present 320/641 (49.9) 159/356 (44.7) 0.11 0.13
Abbreviations: DWI 5 diffusion-weighted imaging; FLAIR 5 fluid-attenuated inversion recovery; IQR 5 interquartile range; LOC 5 level of consciousness;
NIHSS 5 NIH Stroke Scale.
a Result of logistic regression analysis adjusted for country.
bData calculated for number of patients with information available given in parentheses.
c Intracerebral hemorrhage, subarachnoid haemorrhage, intraventricular haemorrhage, hemorrhagic transformation.
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informed consent by proxy ranged from 77.1% in
Spain to 1.2% in Denmark (figure 2).
DISCUSSION In this analysis of baseline data of the
first 1,005 patients enrolled in the WAKE-UP trial,
about 1 in 3 patients were enrolled by proxy consent.
In these cases, consent was provided by the legal
guardian, by next of kin, by an independent consul-
tant, or by the investigator based on an emergency
clause. There were marked differences in clinical
characteristics between patients depending on how
informed consent was obtained. Patients enrolled by
proxy consent were older, more frequently hyper-
tensive, and had more severe stroke symptoms re-
flected by higher NIHSS scores. Patients enrolled by
proxy consent were also about 3.5 times more likely
to be aphasic and 5 times more likely to have a dis-
turbed level of consciousness. These observations are
consistent with previous observations.4,8 Both pre-
stroke conditions (i.e., higher age, more severe co-
morbidity) and stroke-related factors (i.e., more
severe neurologic symptoms including higher rate of
aphasia) contribute to lack of capacity to give
informed consent.
Our findings are consistent with observations
from 2 other trials of IV thrombolysis. In the
National Institute of Neurological Disorders and
Stroke trial, 439 of 624 (70%) patients were enrolled
by proxy consent, and these patients were older and
more severely affected.9 In the first 300 patients
enrolled in the third International Stroke Trial
(IST-3), patients with nonlacunar hemispheric stroke
syndromes and those with a more severe neurologic
deficit were more likely to have been enrolled by
proxy consent.10 Observations of imaging character-
istics have noted smaller DWI volumes and absence
of large artery occlusion among patients without
capacity to consent.14 These results underline that
restricting enrollment to patients with capacity for
consent will systematically exclude specific subgroups
of stroke patients and result in populations that are
not representative of acute stroke patients in gen-
eral.15 In a Cochrane review on information provision
to stroke patients and caregivers, only 10 of 14 ran-
domized controlled trials included in the review
excluded patients with aphasia due to incapacity to
consent.16 In a single-center interventional stroke
trial, inability to consent applied as exclusion criterion
to 330 of 1,194 (28%) patients.17 The effects of such
restrictions include systematic exclusion of patients
with some types of neurologic deficit (e.g., aphasia)
from acute stroke research,8 loss of generalizability,
and slower recruitment rates. Many imaging end-
point biomarkers are likely to be uninformative with
such restrictions.
We focused on a comparison of clinical data
between patients capable of consent and those not
capable without further detailed comparison of the
subgroups of patients enrolled with different ap-
proaches to proxy consent. However, from an ethics
Figure 2 Manner of obtaining informed consent by country
The distribution of the different means of informed consent obtained in WAKE-UP, i.e., either by patients themselves or by
proxy, for the 6 countries participating in the trial at the time of database extraction for the current analysis.
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perspective, there is a fundamental difference between
surrogate consent (category C/D), considered to rep-
resent meaningful patient-centered consent, and phy-
sician consent in the absence of direct or surrogate
consent (category E/F). We performed additional
analyses subdividing the group of patients enrolled
by proxy consent into patient-centered surrogate con-
sent (C/D) and physician consent (E/F). This com-
parison revealed only slight differences in presenting
symptoms, with disturbed level of consciousness
and aphasia being slightly more frequent for physician
consent (20.4% and 79.6%) as compared to patient-
centered surrogate consent (14.9% and 70.1%),
while age, sex distribution, and median NIHSS were
comparable for the 2 subgroups of proxy consent.
Informed consent is considered a fundamental
ethical principle of any research involving humans
as described in the Declaration of Helsinki.1 How-
ever, the Declaration of Helsinki also recognizes the
problem of obtaining informed consent from patients
in critical conditions and suggests different ap-
proaches to informed consent. The Food and Drug
Administration as well as competent authorities in
most European countries allow emergency research
without informed consent under strictly defined cir-
cumstances. Only limited guidance is provided on
how to regulate clinical research in patients incapable
of giving informed consent, and as a consequence
very different approaches for obtaining informed con-
sent are used in different stroke trials and, within
trials, among countries or trial sites.18
At the time of database extraction for the current
analysis, WAKE-UP was running in 6 European
countries: Belgium, Denmark, France, Germany,
Spain, and the United Kingdom. In principle, the
EU directive on clinical trials (EC) No. 2001/20/
EC19 applies to all of these countries, providing rules
for trials in emergency situations. However, the reg-
ulations provided in the directive are ambiguous and
require interpretation. As a consequence, national
regulations and interpretation of these regulations
by institutional review boards and ethics committees
are implemented with heterogeneous results, leading
to a great diversity of national practice with regards to
enrollment of incapable patients in Europe.20 Within
the WAKE-UP trial, we assured that multiple options
for informed consent were available. The use of the 5
available approaches differed among the 6 countries.
Of note, the proportion of proxy consent varied
largely among countries, being hardly used at all in
Denmark (1.2%) but in more than 2-thirds of pa-
tients in Spain (77.1%). Differences in approval of
informed consent for the trial between countries may
partly explain this variation (i.e., no approval for
proxy consent beyond consent by a legal guardian
in Denmark, no approval for consent by investigator
in Germany and the United Kingdom). With regards
to further reasons for the observed variation, we may
only speculate. Differences in the attitude towards
and in experience with different manners of informed
consent among countries may also play a role. Inde-
pendent from underlying reasons, these findings may
inform the conduct of multinational stroke trials in
the future as well as in other disease areas where proxy
consent is likely to be used.
Country effects in clinical trials are generally
assumed to be largely due to chance and small patient
numbers in the individual countries.21 However,
there may be effects that reflect differences in popu-
lations or the clinical setting among countries, result-
ing in differences in patient characteristics or arguably
treatment effect. We observed a confounding effect of
country on the association between the manner of
informed consent and clinical characteristics that ap-
pears plausible in reflecting country-specific aspects of
the trial setting. The observed shorter time delay
between hospital admission and treatment initiation
in patients providing informed consent themselves
appeared to be largely driven by a shorter mean delay
between hospital admission and treatment initiation
in Denmark as compared to all other countries,
together with the fact that in Denmark virtually all
patients were enrolled based on self-consent. These
observations have to be interpreted with caution, as
we cannot rule out potential center-level effects.
However, given this limitation, our observations sug-
gest that the choice of countries in which a trial
should be run may modify the characteristics of the
study population and hence may also influence the
effects of the treatment under investigation.
There are statistical approaches to managing site
differences in clinical trials, which broadly enclose
the options of ignoring possible site effects, or of
modeling them as either fixed effects or random ef-
fects.22 There is, however, no standard solution for
this problem, but the best strategy for controlling site
effects depends on the expected effects, including
confounding and site-by-treatment interaction. In
WAKE-UP, randomization is stratified by site in
order to avoid imbalances between sites concerning
treatment allocation, and site and country will be
addressed as confounding factors in the final statistical
analysis.
The time-critical nature of interventions, the high
prevalence of incapacity in acute stroke, and the
demonstrable effect of proxy consent on trial conduct
and populations call for considering approaches that
might expedite proxy consent procedures for stroke
clinical research, as has been considered in other
emergency conditions.23,24 The Council for Interna-
tional Organizations of Medical Sciences has recently
proposed new international ethical guidelines for
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health-related research involving humans that, among
other issues, address research in emergency settings
and in patients incapable of providing informed con-
sent.25 There is an urgent need for clearer, more
homogeneous, and more pragmatic regulations for
enrollment of incapable patients into clinical trials.
The opinions of stroke patients and caregivers should
also be considered. In prospective interview studies,
a majority of patients agreed to participate in acute
stroke trials without conventional informed con-
sent.26,27 The concept of exception from informed
consent for clinical research in neurologic emergency
conditions like stroke was also generally accepted and
deemed appropriate given approval of institutional
review boards in a qualitative study of several focus
groups including stroke patients, their families, and
healthy young individuals.28
In a large population of patients enrolled in a ran-
domized controlled trial of IV thrombolysis in stroke,
we demonstrate that the manner of informed consent
affects the clinical characteristics of patients. In addi-
tion, the manner of informed consent differed signif-
icantly among countries. These findings illustrate the
importance of identifying strategies for the inclusion
of incapable patients in acute stroke trials. As of yet,
reperfusion treatment is the only effective treatment
strategy for acute stroke, and it is still only available
for a limited subgroup of stroke patients. Further clin-
ical trials improving treatment of acute stroke and
testing new treatment approaches are urgently
needed. Currently, differences in national regulations
and diverging practice to informed consent may ham-
per trial success. More harmonized interpretation and
implementation of international regulations into
national practice is required to enable comparable
practice including all different manners of consent
in an emergency setting among different countries.
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Comment:
Capacity, consent, and country in acute stroke research
In this study, Thomalla et al.1 compare baseline characteristics of participants
providing informed consent with those enrolled by surrogate permission (legal
guardian, next of kin, investigator and independent physician, or just investigator)
from the first 1,005 participants enrolled in WAKE-UP, a multinational European
clinical trial of MRI-based thrombolysis in stroke patients with unknown time of
onset. In accordance with European and national regulations, multiple options for
obtaining consent were made available.
The topic is important—kudos to the investigators for capturing and analyz-
ing data related to manner of consent. Remarkably, 1,005 of 1,039 enrolled
participants had this information available. Indeed, an international consortium
of stroke researchers have recommended recording manner of consent as a core
element in genetic studies to allow explicit consideration of consent status.2
This study confirms prior findings that participants enrolled by surrogate
permission have more severe strokes and also shows more frequent aphasia and
reduced levels of consciousness. While these latter novel findings are not necessar-
ily surprising, they underscore the potential for bias if proxy consent is not
allowed.
Interestingly, the investigators uncovered substantial variation in the manner
of consent across the countries involved. They can only speculate about this sur-
prising finding. Further, a smaller proportion of participants overall was enrolled
by proxy consent than in other studies of acute stroke, suggesting discomfort with
some of these mechanisms. Further research identifying when and why various
forms of proxy consent are or are not allowed, and when and why they are not
utilized even when legally permissible, could help future investigators plan appro-
priately when designing studies in acute stroke and other conditions that have
potential to impair an individual’s ability to provide informed consent for research
participation.3
1. Thomalla G, Boutitie F, Fiebach JB, et al. Effect of informed consent on patient
characteristics in a stroke thrombolysis trial. Neurology 2017;89:1400–1407.
2. Majersik JJ, Cole JW, Golledge J, et al; International Stroke Genetics Consortium.
Recommendations from the International Stroke Genetics Consortium, part 1: stan-
dardized phenotypic data collection. Stroke 2015;46:279–284.
3. Chen DT. Why surrogate consent is important: a role for data in refining ethics policy
and practice. Neurology 2008;71:1562–1563.
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